What changed for Huntington's Disease
A plain English summary of what recently moved in the public data Voxsanity tracks for Huntington's Disease. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 4 to 3 (-1)
- Trials recruiting worldwide 38 to 37 (-1)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Huntington's Disease yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for Huntington's Disease that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05655520 · results posted 17 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 153 participants across two groups: 72 people in "Cohort 1 (Direct Rollover)" and 81 people in "Cohort 2 (Gap Rollover)." These labels suggest participants had previously been in a related study and either moved straight into this one or had a break in between. The trial's primary focus was on tracking unwanted medical events (called treatment-emergent adverse events, or TEAEs — meaning any new or worsening health issue that appeared after starting the study treatment) and on measuring changes in basic physical signs...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT05107128 · results posted 5 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05107128) looked at a drug called SAGE-718 in people with Huntington's disease. A total of 189 people took part — 94 received a placebo (a dummy treatment with no active ingredient) and 95 received SAGE-718. The trial's main focus was on whether SAGE-718 had any effect on a test called the Symbol Digit Modalities Test (SDMT), which measures thinking speed and attention by asking people to match symbols to numbers within 90 seconds. The trial also measured several other things, including daily independence, motor timing, pr...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT05032196 · results posted 12 August 2025
According to the results reported on ClinicalTrials.gov, this trial tested an investigational drug called WVE-003, which is being studied in the context of Huntington's disease. The trial was set up in two parts: a single-dose phase, where participants received one dose at one of three different dose levels (30 mg, 60 mg, or 90 mg) or a placebo (an inactive substance); and a multiple-dose phase, where participants received repeated doses of 30 mg or a placebo. In total, 47 people took part in the single-dose phase and 23 people took part in the multiple-dose phase. The main thing the trial was...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05111249 · results posted 4 November 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05111249) involved 26 people in total — 5 received a placebo (a dummy treatment) and 21 received a medicine called branaplam at a dose of 56 mg. The trial was looking at two main things: whether branaplam changed the level of a harmful protein called mutant huntingtin (mHTT) in the fluid surrounding the brain and spine, and how many participants experienced unwanted health events (called adverse events) during the study. It also tracked changes in brain volume using MRI scans over the course of the study. The reported dat...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03761849 · results posted 7 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03761849) involved people with Huntington's disease and tested a medicine called tovorafenib (also referred to as "Tomi") as well as an earlier investigational medicine called RO7234292, compared against placebo (a dummy treatment with no active ingredient). In total, 899 people were enrolled across six groups. Three of those groups — all receiving either RO7234292 or its placebo — did not complete the study as a group (0 completions recorded), while in the tovorafenib and its placebo groups, between 207 and 216 out of rou...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03515213 · results posted 28 September 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 10 people in total — 9 in the active treatment group and 1 in the placebo group. All 10 participants completed the trial with no dropouts. The trial was investigating a treatment for Huntington's disease, and its main focus was on measuring changes in the levels of a specific protein and its genetic instructions (called PGC-1alpha) in participants' bodies over 6 months. Several secondary measures were also tracked, including a blood level of the study drug, as well as scores on standard Huntington's disease rating sca...
-
NCT03842969 · results posted 31 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03842969) looked at a drug called tominersen, given at different dosing schedules to people with Huntington's disease. A total of 236 participants took part across three groups: 17 received the drug every 4 weeks (Q4W), 138 received it every 8 weeks (Q8W), and 81 received it every 16 weeks (Q16W). The trial was measuring things related to safety and tolerability — including unwanted health events that occurred during treatment, any signs of suicidal thoughts or behaviours, and changes in thinking and memory using a standar...
-
NCT03225846 · results posted 25 April 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03225846) enrolled 88 people in total across seven groups. Twenty-two participants received a pooled placebo (a dummy treatment), while the remaining 66 received one of six different doses of an investigational drug called WVE-120102, ranging from 2 mg up to 32 mg. The trial was primarily set up to track the number of participants who experienced unwanted health events (called "adverse events") during the study, including those that were severe or serious. It also measured how the drug moved through the body — for example,...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03225833 · results posted 10 February 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03225833) enrolled 61 people in total across six groups: 16 received a placebo (an inactive substance used for comparison), and the remaining 45 received one of five different doses of an experimental drug called WVE-120101 — either 2 mg, 4 mg, 8 mg, 16 mg, or 32 mg. The trial was primarily measuring how many participants experienced unwanted medical events (called adverse events) after receiving the drug or placebo, and also tracked how the drug moved through the body over time. The reported data shows that when it came...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01306929 · results posted 9 February 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT01306929) enrolled 134 people with Huntington's Disease, all of whom received the study drug pridopidine. The trial was measuring two main things: how many participants experienced at least one unwanted or unexpected health event (called an adverse event) during the study, and how participants' movement and motor abilities changed over time, as measured by a standard Huntington's Disease rating tool. Of the 134 people who started, 40 completed the study, while 94 did not complete it — though the reasons for this were not d...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04617860 · results posted 9 February 2022
According to the results reported on ClinicalTrials.gov, this trial tested a drug called WVE-120102 in 36 people across three starting dose groups — 8 people began on 4 mg, 10 on 8 mg, and 18 on 16 mg. During the trial, many participants had their doses increased over time, with some eventually receiving 32 mg. The trial was measuring safety and tolerability — in other words, it was tracking what kinds of unwanted health events occurred while people were taking the drug and at what doses. Notably, none of the 36 participants completed the trial; all either withdrew or did not finish for other...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04617847 · results posted 9 February 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT04617847) tested a medicine called WVE-120101 across different doses — 4 mg, 16 mg, and 32 mg. A total of 27 people started the trial (3 in the 4 mg group and 24 in the 16 mg group). Some participants later had their dose adjusted upward during the study. No participants were recorded as having completed the trial in the formal sense, and all were listed under "not completed," though this may reflect how the trial was structured or ended rather than dropouts alone. The reported data shows that the primary focus of this tr...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT02494778 · results posted 17 September 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02494778) enrolled 248 people who received pridopidine at a dose of 45 mg twice daily. Of those who started, 27 completed the study and 221 did not complete it. The trial ran for up to 106 weeks and was measuring, among other things, any unwanted or unexpected health events (called adverse events) that participants experienced, as well as changes in certain motor (movement) functions measured using specialised sensors on the hands. The reported data shows that out of 248 participants, 193 experienced at least one adverse...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02006472 · results posted 19 July 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02006472) tested four different doses of a drug called pridopidine — 45 mg, 67.5 mg, 90 mg, and 112.5 mg (each taken twice daily) — against a placebo (inactive treatment) in people with Huntington's disease. Around 408 people were enrolled across the five groups at the start of the trial, with roughly 81–82 people in each group. The trial ran in two periods: the first up to 26 weeks, and the second continuing to 52 weeks. The main thing being measured was a standardised motor (movement) score called the UHDRS Total Motor S...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03342053 · results posted 19 January 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03342053) involved 46 people in total — 23 who received the study drug RO7234292 once a month, and 23 who received it once every two months. The drug was delivered directly into the fluid around the spine (a method called intrathecal administration). The trial was measuring, among other things, how often participants experienced adverse events (unwanted health events that occurred during the study), as well as levels of a specific protein in the spinal fluid, and changes in brain structure over 15 months. The reported dat...
-
NCT00652457 · results posted 5 January 2021
According to the results reported on ClinicalTrials.gov, this trial involved 50 people in total — 23 in one group and 27 in another. The study used a "crossover" design, meaning one group received the medication memantine throughout the trial, while the other group started on a placebo (an inactive treatment) before switching to memantine. All 50 participants completed the study with no drop-outs recorded. The trial was measuring cognitive function — specifically memory — using a test called the Hopkins Verbal Learning Test – Revised (HVLT-R), as well as behavioural symptoms using a tool calle...
-
NCT01897896 · results posted 16 April 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT01897896) looked at a medication called SD-809 ER in people with a movement disorder. There were two groups of participants: an 82-person "Rollover Cohort" (people who had been in an earlier related trial and continued onto this one) and a 37-person "Switch Cohort" (people who switched from a different form of the medication). In total, 119 people started the study. Of those, 56 people in the Rollover Cohort and 25 in the Switch Cohort completed it. The trial's main focus was on tracking and counting any unwanted medical e...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01806896 · results posted 14 December 2017
According to the results reported on ClinicalTrials.gov, this trial involved 37 people in total — 20 were assigned to take PF-02545920 (20 mg twice a day) and 17 were assigned to take a placebo (a dummy pill with no active ingredient), also twice a day. The trial was primarily measuring safety-related observations, including any unwanted medical events that occurred during the study, unusual results on blood and urine tests, changes in heart readings (ECGs), changes in blood pressure and pulse, and changes in body weight. The reported data shows that when it came to unwanted medical events (c...
-
NCT00920699 · results posted 25 September 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 91 people in total, split across three groups based on their daily dose of a supplement called CoQ10 (Coenzyme Q10): 29 people took 600 mg per day, 30 took 1,200 mg per day, and 32 took 2,400 mg per day. The trial was primarily measuring tolerability — that is, how many participants were able to stay on their originally assigned dose throughout the study without any changes to it. It also measured two things in the blood: levels of CoQ10 itself, and levels of a substance called 8OHdG, which the researchers were tracki...
-
NCT01795859 · results posted 11 August 2017
According to the results reported on ClinicalTrials.gov, this trial (NCT01795859) involved 90 people in total — 45 who received a tablet called SD-809 and 45 who received a placebo (a dummy tablet with no active ingredient). Nearly all participants finished the trial: 44 in the SD-809 group and 43 in the placebo group. The trial was measuring changes in involuntary movements (called chorea) in people with Huntington's disease, using a scoring system called the Total Maximal Chorea (TMC) scale, which runs from 0 to 28, where a lower score means fewer involuntary movements. The reported data sh...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01590888 · results posted 18 July 2016
According to the results reported on ClinicalTrials.gov, this trial (NCT01590888) looked at a drug called PBT2 in people with Huntington's disease. A total of 109 people took part — 36 received the higher dose of PBT2 (250 mg), 38 received the lower dose (100 mg), and 35 received a sugar pill (placebo). The trial's main goal was to measure how many participants in each group experienced at least one unwanted or unexpected health event (called an adverse event) while taking the treatment. It also measured changes in thinking skills, movement, everyday functioning, behaviour, and an overall impr...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00608881 · results posted 30 March 2016
According to the results reported on ClinicalTrials.gov, this trial looked at a high-dose form of a supplement called Coenzyme Q10 (2,400 mg per day) compared to a placebo (a dummy treatment with no active ingredient) in people with Huntington's disease. A total of 609 people took part — 303 in the Coenzyme Q10 group and 306 in the placebo group. The trial ran for 60 months (five years). The main thing being measured was a combined score that took into account both how long participants survived and how well they could manage everyday tasks and independent living — this was called a "joint ran...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01882062 · results posted 24 March 2016
According to the results reported on ClinicalTrials.gov, this trial enrolled 10 participants, and all 10 completed the study. The trial was looking at the effect of a dietary supplement called triheptanoin, taken at a dose of 1 gram per kilogram of body weight per day for one month. The main thing being measured was how the brain uses energy — specifically, a ratio called Pi/PCr (the balance between two energy-related chemicals in the brain, inorganic phosphate and phosphocreatine). This ratio is used as a way of gauging how well the brain's energy-producing processes are working during activi...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00277355 · results posted 19 April 2013
According to the results reported on ClinicalTrials.gov, this trial looked at whether minocycline (an antibiotic taken at 100 mg twice a day) might slow the progression of Huntington's disease compared to a placebo (a dummy pill with no active ingredient). A total of 114 people took part — 87 in the minocycline group and 27 in the placebo group. Of those, 73 in the minocycline group and 22 in the placebo group completed the study. The main thing being measured was change in something called the Total Functional Capacity (TFC) scale, which is part of a standard Huntington's disease rating tool....
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, Huntington's Disease currently attracts a substantial level of public research investment from the United States, and that funding has remained broadly steady from year to year. This pattern suggests that the scientific community continues to view Huntington's Disease as a meaningful research priority, with no sharp decline in institutional support. For patients, a s...
See the full Huntington's Disease page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.